Galarubicin
Alternative Names: DA 125Latest Information Update: 08 Sep 2015
At a glance
- Originator Dong-A Pharmaceutical
- Developer Dong-A Pharmaceutical; Dong-A ST
- Class Anthracyclines; Antineoplastics; Doxorubicins
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer metastases; Leukaemia; Non-small cell lung cancer